have calculated that 58% of the variation in radio graphic bone erosion progression rates among patients with RA is due to genetics (P = 0.003). If more severe disease is geneti cally distinct from a milder course, it might be possible to identify those patients at greatest risk of damage. Clinical realization of this genetic potential, however, will be a challenge. Serological markers, including rheuma toid factor (RF) and anti citrullinated protein antibodies (ACPA), and inflam matory markers including ethrythrocyte sedimentation rate and Creactive protein level, correlate with disease severity and joint destruction. 2, 3 Despite being the most common RA biomarkers in clinical use, however, none are highly predictive of disease severity and their utility for prognos is in clinical practice is limited. 4 The genetic component of susceptibi lity to RA has long been appreciated; 5 fami lial studies implied high heritability of dis ease risk, which has been borne out in sub sequent studies. Overall heritability of RA is thought to be roughly 65% (Box 1). There fore, a family history of RA is an important part of the clinical evaluation of patients with the disease. Genetic associa tion studies for RA susceptibility have been remarkably successful, identifying risk alleles within the MHC and throughout the genome. These discoveries have added to our understanding of the aetiology and pathogenesis of disease, and promise to facilitate the de velopment of new targeted therapies.
In contrast to RA risk, however, rela tively little research into the genetics of dis ease severity has been done to date. Assessing factors that predispose to a more (or less) severe disease course is difficultc hallenges include a lack of large cohorts of patients with RA who have been clini cally characterized in a consistent manner, the difficulty in recruiting large samples of their affected relatives with clinical data, and difficulty in measuring and adjusting for challenging confounders such as health care access and treatment course. Several studies have tested whether candidate locus alleles, including RA risk alleles, correlate with disease severity, but the results have been mixed. 6 If genetic predictors of joint damage severity could be discovered, then they might serve as extremely useful bio markers. Genetic markers offer key advan tages over inflammatory markers; they are amenable to highthroughput assay and are stable over time and treatment course. Moreover, identifying genes that are asso ciated with disease severity would shed further light on the pathophysiology of RA, particularly of severe disease.
If disease progression or severity were influenced strongly by genetic factors, then it should be a familial trait-that is, on average, closely related individuals should present more similar disease courses than unrelated individuals. A twin study in 2006 found suggestive evidence of familiality of radiographic joint destruction in patients with RA. Van der Helmvan Mil and col leagues 7 found that ten monozygotic twin pairs had more similar Sharp-van der Heijde scores (which quantify the sever ity of joint destruction in RA on the basis of hand and foot radiographs) than eight NATURE REVIEWS | RHEUMATOLOGY VOLUME 8 | JUNE 2012 | 313
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Box 1 | Modelling heritability and familiality of complex traits
Physical traits that are influenced by many independent factors are often normally distributed, including most quantitative traits, such as height. For a disease trait (in which the phenotype is binary, being either affected or unaffected), quantitative geneticists assume that a normally distributed underlying phenotype, termed liability, manifests as disease when it exceeds a threshold determined by the prevalence of disease. An individual's phenotype is essentially the sum of environmental and genetic variables, and so the population distribution of phenotypes can be viewed as the sum of two distributions-genetic and environmental components. If the quantitative trait is normalized to have a mean of zero and variance of one, then the distributions of the genetic and environmental components of the trait will have variances equal to the heritability, and to one minus the heritability, respectively. Related individuals have correlated genetic values for a quantitative trait. For example, monozygotic twins have the exact same genetic values, and siblings' genetic values have a correlation of 0.5. Relatives' phenotypic correlations, then, are their genetic correlations, reduced by the contribution of environment (that is, their relatedness multiplied by the heritability of the trait, which is between zero and one). Concordance for a binary disease trait can be mathematically transformed to phenotypic correlation on the underlying liability scale, and used to derive the relationship between concordance rate ratio (the proportion of first-degree relatives of patients who are also affected by the disease, over the population prevalence) and heritability. As these analyses do not account for the possibility that close relatives might also have correlated environmental values, twin studies often compare monozygotic and dizygotic twins in order to control for this confounding. MacGregor et al. 10 estimated heritability from monozygotic and dizygotic twins jointly, accounting for shared environment, and estimated heritability for rheumatoid arthritis to be ~65%. dizygotic twins, although the study was small and the difference was not significant.
The study by Knevel et al. 1 used Icelandic databases that offer uniquely comprehen sive insights into population genetics. Related ness was found to be a signifi cant predictor of differences in the rate of joint destruction (measured by changes in the Sharpvan der Heijde score over the years since diagno sis) in a sample of >250 patients with RA, leading to an estimated 58% heritability for the rate of bone erosion progression in RA.
Knevel and colleagues utilized the research cohort of the Landspitali National University Hospital of Iceland, in which 325 patients with RA had radiographs avail able, the unique resource of the Icelandic genealogy records, as well as genomewide singlenucleotide polymorphism genotype data (collected by deCODE Genetics) 8 avail able for 267 of the patients. 1 Investigators have leveraged the unique advantages of the deCODE genetics cohort-which include a fairly isolated population with a national ized healthcare system and excellent genea logical records-to make rapid progress in answering many challenging questions in complex trait genetics.
8 Knevel et al. 1 demon strated a correlation between pair wise differences in joint destruction rates and pairwise genetic relatedness assessed using both genealogyderived kinship coeffi cients and identitybydescent esti mates based on the genotype data. These estimates assess realized relatedness, which can vary substantially among (for example) nonidentical siblings due to random Mendelian segregation. 9 Consistent with a bona fide genetic contribution to the rate of joint destruction, the identitybydescent analysis yielded a greater and more statis tically significant estimate of heritability (58%, P = 0.003) than that arrived at using genealogyderived kinship coefficients (45%, P = 0.018). Providing additional sup porting evidence that RA severity is herit able, the results will motivate investigators to pursue further studies to identify the underlying genetic factors.
We note certain limitations to the study. The patients whose data were available to Knevel et al. 1 included both ACPA posi tive and ACPA negative individuals, and analyses within ACPA status strata were equivocal. This area is important for future investigation, because positive ACPA status correlates with increased disease sever ity and is associated with different genetic susceptibility factors. In addition, possible confounding by environmental factors, including healthcare access (through indivi dual family habits as well as socioeconomic status) and treatment strategy could not be adjusted for. The authors noted that most of the sampled data came from before the era of aggressive treatment, and that variation in treatment probably does not have a major role in their cohort. 1 In summary, this populationbased study by Knevel et al. 1 adds to the mounting evi dence for the genetic basis of the severity of joint erosion in RA. A genetic component for disease severity would suggest that rela tives of patients with severe RA, in addition to being more likely to develop disease, are also more likely to develop severe erosive RA. Currently, little can be done to prospec tively predict disease severity. These results imply that better biomarkers (includ ing genetic markers) might be found for RA severity and prognosis, and that the for mid able arsenal of genomic medicine can be brought to bear specifically on severe, erosive disease.
